Inclusion Criteria:

- Histologically or cytologically proven adenocarcinoma of the pancreas

- Evaluable disease

- Must have received 3-4 months of gemcitabine-based chemotherapy and have had stable
disease by RECIST criteria. Regimens include:

- gemcitabine alone

- gemcitabine and erlotinib

- gemcitabine and oxaliplatin

- gemcitabine and cisplatin

- gemcitabine and capecitabine

- 18 years of age or older

- Life expectancy of greater than 4 months

- ECOG Performance Status 0-1

- Normal organ and marrow function as outlined in the protocol

- Ability to drink at least 2 liters of fluid daily

- Women of child-bearing potential and men must agree to use adequate contraception
prior to study entry and for the duration of study participation

- Patients must be able to swallow capsules

Exclusion Criteria:

- Chemotherapy within 3 weeks prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier

- Participants may not be receiving any other study agents

- Known distant metastases to any organ

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to vorinostat or 5-FU

- Patients taking warfarin due to potential interactions of both 5-FU and vorinostat.
Low molecular weight heparin should be substituted when appropriate

- Patients who have received upper abdominal radiation therapy which fields would
overlap with that determined necessary to treat the primary tumor.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant or breastfeeding women

- Individuals with history of a different malignancy are ineligible unless they are
deemed by the investigator to be at low risk of recurrence of that malignancy.
Patients may not have a concurrent second malignancy.

- Active HIV or hepatitis

- Prior exposure to HDAC inhibitor (except valproic acid, provided there is a 30 day
washout period)